SLNO

Soleno Therapeutics Inc

Apr 06 • 02:24PM ET

52.30

+12.81 32.44 %

Healthcare • Biotechnology • USA • NASD

Today, 7:05 AMSoleno Therapeutics to be acquired by Neurocrine Biosciences for $53 per share in cash, valuing deal at about $2.9 billion

Peers: VKTX RZLT MDGL LGND KURA ARDX ASRT ENTA PDSB BTAI

| Held by: XBI VTI IWM VXF IWO SCHA VTWO VHT LABU ITOT

Scroll to Statements

Index	RUT	P/E	234.63	EPS (ttm)	0.22	Insider Own	3.96%	Shs Outstand	52.29M	Perf Week	74.04%
Market Cap	2.70B	Forward P/E	7.86	EPS next Y	6.66	Insider Trans	-0.69%	Shs Float	49.58M	Perf Month	35.60%
Enterprise Value	2.45B	PEG	0.04	EPS next Q	0.68	Inst Own	125.32%	Short Float	18.82%	Perf Quarter	10.88%
Income	20.48M	P/S	14.18	EPS this Y	918.45%	Inst Trans	-0.39%	Short Ratio	5.53	Perf Half Y	-9.80%
Sales	190.41M	P/B	6.08	EPS next Y	67.60%	ROA	4.58%	Short Interest	9.33M	Perf YTD	12.96%
Book/sh	8.61	P/C	8.84	EPS next 5Y	186.15%	ROE	5.89%	52W High	90.32 -42.09%	Perf Year	-22.50%
Cash/sh	5.92	P/FCF	57.86	EPS past 3/5Y	- -	ROIC	4.08%	52W Low	29.43 77.71%	Perf 3Y	2043.44%
Dividend Est.	-	EV/EBITDA	144.20	Sales past 3/5Y	- -	Gross Margin	98.32%	Volatility	9.98% 6.50%	Perf 5Y	185.79%
Dividend TTM	-	EV/Sales	12.85	EPS Y/Y TTM	105.97%	Oper. Margin	7.85%	ATR (14)	3.22	Perf 10Y	-41.40%
Dividend Ex-Date	-	Quick Ratio	5.55	Sales Y/Y TTM	-	Profit Margin	10.75%	RSI (14)	77.84	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	5.80	EPS Q/Q	162.02%	SMA20	48.14%	Beta	-2.80	Target Price	95.25
Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	-	SMA50	37.06%	Rel Volume	40.05	Prev Close	39.49
Employees	182	LT Debt/Eq	0.12	Earnings	Feb 25 AMC	SMA200	-8.54%	Avg Volume	1.69M	Price	52.30
IPO	Nov 13, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.55% 3.36%	Trades		Volume	51,729,005	Change	32.44%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wolfe Research	Outperform	$75
Oct-07-25	Initiated	Goldman	Buy	$125
Aug-20-25	Initiated	Wells Fargo	Overweight	$123
Jun-23-25	Initiated	TD Cowen	Buy	$110
Mar-05-25	Resumed	Stifel	Buy	$74
Dec-02-24	Reiterated	Stifel	Buy	$74
Dec-02-24	Reiterated	Robert W. Baird	Outperform	$72
Sep-03-24	Initiated	H.C. Wainwright	Buy	$70
May-10-24	Initiated	Robert W. Baird	Outperform	$72
Feb-05-24	Initiated	Piper Sandler	Overweight	$93
Jan-23-24	Initiated	Stifel	Buy	$63
Nov-21-23	Resumed	Guggenheim	Buy	$40
Sep-29-20	Initiated	Guggenheim	Buy	$8
Jan-10-20	Initiated	Craig Hallum	Buy	$8
Dec-23-19	Initiated	Oppenheimer	Outperform	$10
Feb-13-18	Reiterated	Maxim Group	Buy	$8 → $4

Show Previous Ratings

Today 02:02PM	Stock Bounce Fades, Oil Climbs on Trumps Remarks: Markets Wrap (Bloomberg) +32.44%
10:30AM	BC-Most Active Stocks (Associated Press)
09:35AM	Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal (Proactive)
08:58AM	SLNO Jumps As Deal Buzz Lifts Stocks (GuruFocus.com)
07:34AM	Neurocrine to Buy Soleno for $2.9 Billion (The Wall Street Journal)
07:24AM	Loading…
07:24AM	This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. (Barrons.com)
07:18AM	Soleno Therapeutics climbs on deal news, and more stocks on the move (MarketWatch)
07:12AM	Neurocrine to buy Soleno Therapeutics for $2.9 billion (Reuters)
07:04AM	Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move. (MarketWatch)
07:00AM	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio (PR Newswire)
05:56AM	These Stocks Are Today's Movers: Intel, Micron, Paramount, Strategy, Soleno Therapeutics, and More (Barrons.com)
Apr-01-26 03:43PM	Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman (PR Newswire) +10.48%
Mar-16-26 03:03AM	Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO (PR Newswire)
Mar-12-26 09:00AM	SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt (PR Newswire) -5.92%
04:40AM	Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO (PR Newswire)
08:00AM	Loading…
Mar-10-26 08:00AM	Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SLNO (Business Wire)
Mar-09-26 08:31PM	H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating (Insider Monkey)
Mar-04-26 02:30AM	Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy (Insider Monkey)
Mar-01-26 04:27AM	Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 - Here's Why (Insider Monkey)
Feb-26-26 12:33PM	Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) -7.12%
08:00AM	Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer (GlobeNewswire)
03:08AM	Soleno Therapeutics Q4 Earnings Call Highlights (MarketBeat)
12:04AM	Soleno Therapeutics Inc (SLNO) Q4 2025 Earnings Call Highlights: Achieving Profitability and ... (GuruFocus.com)
Feb-25-26 04:01PM	Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT XR (GlobeNewswire)
Feb-19-26 12:42PM	Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market (Benzinga)
Feb-16-26 12:24PM	Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance (Insider Monkey)
Feb-15-26 06:39AM	Soleno Therapeutics Updates PWS Launch, Reimbursement Trends and EU Review at Guggenheim Summit (MarketBeat)
Feb-11-26 08:00AM	Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks) +9.75%
09:35AM	Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround (Zacks)
10:24AM	Loading…
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
Jan-29-26 08:00AM	Soleno Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Jan-27-26 12:59PM	HCA Healthcare Q4 Earnings Beat Estimates on Strong Patient Volumes (Zacks)
07:22AM	Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge (Insider Monkey)
Jan-23-26 04:56AM	Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now? (Insider Monkey)
Jan-22-26 10:21PM	Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside (Insider Monkey)
Jan-14-26 09:55AM	Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-13-26 04:28AM	New Strong Buy Stocks for January 13th (Zacks)
Jan-12-26 07:00AM	Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Jan-09-26 03:16AM	Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts (Insider Monkey) -5.49%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-06-26 08:00AM	Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)? (Insider Monkey)
Jan-05-26 08:00AM	Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT XR in the Journal of Clinical Endocrinology and Metabolism (GlobeNewswire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +5.07%
Dec-10-25 10:32AM	Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026? (Insider Monkey)
Dec-03-25 04:05PM	Soleno Therapeutics Announces the Passing of Board Member William G. Harris (GlobeNewswire) +5.41%
Nov-30-25 12:26AM	Analyst Dismisses ViCAT XR Safety Fears, Expects Strong Growth Despite Recent Stock Weakness (Insider Monkey)
Nov-25-25 08:39AM	Soleno Therapeutics (SLNO) Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns (Insider Monkey) +8.41%
Nov-24-25 08:00AM	Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-21-25 05:22AM	Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns (Insider Monkey)
Nov-11-25 07:00AM	Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement (GlobeNewswire) +5.16%
Nov-07-25 10:04AM	Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman (PR Newswire) +9.55%
Nov-06-25 12:07PM	Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings (Insider Monkey) -7.10%
Nov-05-25 06:26AM	Soleno slumps despite sales uptick; Madrigals MASH drug continues ascent (BioPharma Dive) -26.59%
12:03AM	Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Call Highlights: Profitability Achieved Amidst ... (GuruFocus.com)
Nov-04-25 04:01PM	Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR (GlobeNewswire)
Nov-03-25 07:28AM	Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 08:00AM	Soleno Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire)
Oct-22-25 05:01PM	Soleno Therapeutics, Inc. (SLNO): A Bull Case Theory (Insider Monkey)
Oct-21-25 08:00AM	Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET (GlobeNewswire)
Oct-17-25 09:54PM	Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating (Insider Monkey)
Oct-13-25 08:00AM	Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors (GlobeNewswire)
Oct-07-25 01:05PM	Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT (Insider Monkey) +6.26%
Sep-30-25 04:01AM	Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123 (Insider Monkey)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
10:23AM	Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial (Insider Monkey)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) +13.46%
07:28AM	Acadia to scrap Prader-Willi drug after study setback (BioPharma Dive)
Sep-18-25 10:38AM	Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands (Insider Monkey) +10.98%
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive) -5.47%
Sep-11-25 09:35AM	Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.49%
02:18AM	Soleno Therapeutics (SLNO) Falls Hard on Patient Death (Insider Monkey)
Sep-10-25 12:59AM	Here's Why Analysts are Bullish on Soleno Therapeutics (SLNO) (Insider Monkey) -14.52%
Aug-27-25 08:00AM	Soleno Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-20-25 04:02PM	Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman (PR Newswire)
09:34AM	Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls (The Fly)
Aug-19-25 09:35AM	Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround (Zacks)
Aug-15-25 09:57AM	Soleno Therapeutics stock falls after Scorpion Capital short report (Investing.com) -7.41%
Aug-11-25 09:55AM	How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% (Zacks)
08:50AM	Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going (Zacks)
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 08:00AM	Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET (GlobeNewswire)
Jul-25-25 12:00PM	Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy? (Zacks)
Jul-23-25 09:55AM	Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength (Zacks)
Jul-21-25 12:15AM	Soleno Therapeutics' Vykat XR Exceeds Sales Expectations (Insider Monkey)
Jul-10-25 09:59AM	Soleno sales of new Prader-Willi drug rise faster than expected (BioPharma Dive) -9.23%
09:07AM	Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (GlobeNewswire)
06:01AM	Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock (GlobeNewswire)
06:00AM	Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 (GlobeNewswire)
Jul-01-25 08:00AM	Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 (GlobeNewswire)
Jun-26-25 03:24PM	TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy (Insider Monkey)
Jun-25-25 08:00AM	Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
Jun-23-25 09:38AM	DoorDash, AMD upgraded: Wall Street's top analyst calls (The Fly)
Jun-20-25 08:00AM	Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
May-26-25 09:16AM	EMA validates Solenos application for Prader-Willi syndrome treatment (Pharmaceutical Technology)
May-23-25 05:40PM	Soleno Therapeutics seeking regulatory approval in treatment of PWS (TipRanks)
01:55AM	Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR (Insider Monkey)

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Meredith	Chief Commercial Officer	Mar 27 '26	Sale	30.44	7,522	228,980	64,507	Mar 31 08:17 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '26	Sale	30.44	6,582	200,365	39,823	Mar 31 08:15 PM
Abingworth Bioventures VII LP	Shareholder	Aug 11 '25	Proposed Sale	82.15	1,347,522	110,696,581		Aug 15 09:00 PM
Hirano Patricia C	SEE REMARKS	Jul 01 '25	Sale	82.76	3,830	316,971	13,206	Jul 03 04:41 PM
PATRICIA HIRANO	Officer	Jul 01 '25	Proposed Sale	82.76	3,830	316,971		Jul 01 04:03 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Option Exercise	44.25	266	11,770	17,302	Jun 26 06:04 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Sale	84.25	266	22,410	17,036	Jun 26 06:04 PM
PATRICIA HIRANO	Officer	Jun 24 '25	Proposed Sale	84.25	266	22,410		Jun 24 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLNO

Soleno Therapeutics Inc

Upgrade your Finviz experience